vs
Orion S.A.（OEC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Orion S.A.的1.5倍（$622.0M vs $411.7M），Royalty Pharma plc同比增速更快（4.8% vs -5.2%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -9.5%）
奥里昂集团成立于1917年，总部位于芬兰埃斯波，是一家全球化运营的芬兰企业。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下所有生产基地及大部分研发部门均设于芬兰境内。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
OEC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$411.7M
营收增速更快
RPRX
高出10.0%
-5.2%
两年增速更快
RPRX
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.7M | $622.0M |
| 净利润 | — | $214.2M |
| 毛利率 | 18.9% | — |
| 营业利润率 | 4.3% | 62.4% |
| 净利率 | — | 34.4% |
| 营收同比 | -5.2% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $-0.36 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OECRPRX
| Q4 25 | $411.7M | $622.0M | ||
| Q3 25 | $450.9M | $609.3M | ||
| Q2 25 | $466.4M | $578.7M | ||
| Q1 25 | $477.7M | $568.2M | ||
| Q4 24 | $434.2M | $593.6M | ||
| Q3 24 | $463.4M | $564.7M | ||
| Q2 24 | $477.0M | $537.3M | ||
| Q1 24 | $502.9M | $568.0M |
净利润OECRPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $-67.1M | $288.2M | ||
| Q2 25 | $9.0M | $30.2M | ||
| Q1 25 | $9.1M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $-20.2M | $544.0M | ||
| Q2 24 | $20.5M | $102.0M | ||
| Q1 24 | $26.7M | $4.8M |
毛利率OECRPRX
| Q4 25 | 18.9% | — | ||
| Q3 25 | 19.0% | — | ||
| Q2 25 | 21.1% | — | ||
| Q1 25 | 20.5% | — | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 23.2% | — | ||
| Q2 24 | 23.0% | — | ||
| Q1 24 | 24.3% | — |
营业利润率OECRPRX
| Q4 25 | 4.3% | 62.4% | ||
| Q3 25 | -11.9% | 70.1% | ||
| Q2 25 | 6.9% | 36.3% | ||
| Q1 25 | 6.5% | 94.0% | ||
| Q4 24 | 5.4% | 60.9% | ||
| Q3 24 | -3.3% | — | ||
| Q2 24 | 8.7% | 50.2% | ||
| Q1 24 | 10.5% | -13.0% |
净利率OECRPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | -14.9% | 47.3% | ||
| Q2 25 | 1.9% | 5.2% | ||
| Q1 25 | 1.9% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | -4.4% | 96.3% | ||
| Q2 24 | 4.3% | 19.0% | ||
| Q1 24 | 5.3% | 0.8% |
每股收益（稀释后）OECRPRX
| Q4 25 | $-0.36 | $0.49 | ||
| Q3 25 | $-1.20 | $0.67 | ||
| Q2 25 | $0.16 | $0.07 | ||
| Q1 25 | $0.16 | $0.55 | ||
| Q4 24 | $0.31 | $0.46 | ||
| Q3 24 | $-0.35 | $1.21 | ||
| Q2 24 | $0.35 | $0.23 | ||
| Q1 24 | $0.45 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $60.7M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $384.6M | $9.7B |
| 总资产 | $1.9B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资OECRPRX
| Q4 25 | $60.7M | $618.7M | ||
| Q3 25 | $51.3M | $938.9M | ||
| Q2 25 | $42.6M | $631.9M | ||
| Q1 25 | $37.5M | $1.1B | ||
| Q4 24 | $44.2M | $929.0M | ||
| Q3 24 | $53.2M | $950.1M | ||
| Q2 24 | $34.2M | $1.8B | ||
| Q1 24 | $43.9M | $843.0M |
总债务OECRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益OECRPRX
| Q4 25 | $384.6M | $9.7B | ||
| Q3 25 | $401.8M | $9.6B | ||
| Q2 25 | $466.5M | $9.5B | ||
| Q1 25 | $466.1M | $9.8B | ||
| Q4 24 | $474.9M | $10.3B | ||
| Q3 24 | $476.3M | $10.3B | ||
| Q2 24 | $503.9M | $9.8B | ||
| Q1 24 | $492.2M | $9.9B |
总资产OECRPRX
| Q4 25 | $1.9B | $19.6B | ||
| Q3 25 | $2.0B | $19.3B | ||
| Q2 25 | $2.0B | $18.3B | ||
| Q1 25 | $2.0B | $17.6B | ||
| Q4 24 | $1.9B | $18.2B | ||
| Q3 24 | $2.0B | $18.0B | ||
| Q2 24 | $1.9B | $17.7B | ||
| Q1 24 | $1.9B | $16.1B |
负债/权益比OECRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $44.2M | — |
| 自由现金流率自由现金流/营收 | 10.7% | — |
| 资本支出强度资本支出/营收 | 11.8% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $54.8M | — |
8季度趋势，按日历期对齐
经营现金流OECRPRX
| Q4 25 | $92.9M | $827.1M | ||
| Q3 25 | $68.8M | $702.6M | ||
| Q2 25 | $53.7M | $364.0M | ||
| Q1 25 | $400.0K | $596.1M | ||
| Q4 24 | $94.5M | $742.5M | ||
| Q3 24 | $-30.9M | $703.6M | ||
| Q2 24 | $29.3M | $658.2M | ||
| Q1 24 | $32.4M | $664.6M |
自由现金流OECRPRX
| Q4 25 | $44.2M | — | ||
| Q3 25 | $27.9M | — | ||
| Q2 25 | $11.5M | — | ||
| Q1 25 | $-28.8M | — | ||
| Q4 24 | $23.5M | — | ||
| Q3 24 | $-78.8M | — | ||
| Q2 24 | $-25.4M | — | ||
| Q1 24 | $-700.0K | — |
自由现金流率OECRPRX
| Q4 25 | 10.7% | — | ||
| Q3 25 | 6.2% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | -17.0% | — | ||
| Q2 24 | -5.3% | — | ||
| Q1 24 | -0.1% | — |
资本支出强度OECRPRX
| Q4 25 | 11.8% | — | ||
| Q3 25 | 9.1% | — | ||
| Q2 25 | 9.0% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 11.5% | — | ||
| Q1 24 | 6.6% | — |
现金转化率OECRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 5.97× | 12.06× | ||
| Q1 25 | 0.04× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 1.43× | 6.45× | ||
| Q1 24 | 1.21× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OEC
| Rubber | $272.0M | 66% |
| Specialties | $139.7M | 34% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
